T-cell Prolymphocytic Leukemia, Cerebriform Variant.

Cureus

Internal Medicine, Unidade Local de Saúde do Alto Minho (ULSAM), Viana do Castelo, PRT.

Published: February 2021

T-cell prolymphocytic leukemia (T-PLL) is a very rare and aggressive lymphoproliferative disorder. We present a 70-year-old man with complaints of fatigue, low urinary output, and peripheral edema for one month. Objectively, he presented diminished respiratory sounds bilaterally and peripheral edema. Analytical study revealed mild anemia and mild lymphomonocytosis, acute kidney injury, and urinalysis with proteins, leukocytes, erythrocytes, and cylinders. Chest radiography was consistent with pleural effusion. Subsequent study showed new onset of thrombocytopenia with a progressive increase of lymphocytosis, in association with inguinal adenopathies and splenomegaly. Immunophenotypic study of peripheral blood and lymph node biopsy were compatible with the diagnosis of T-PLL. Negative serology for human T-cell lymphotropic virus type 1 (HTLV-1) excluded adult T-cell leukemia. Progressive changes in the peripheral blood smear were seen, finally showing the presence of lymphocytes with a cerebriform nucleus, revealing this variant. There was a rapid catastrophic progression, spontaneous tumor lysis syndrome, and death.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956018PMC
http://dx.doi.org/10.7759/cureus.13299DOI Listing

Publication Analysis

Top Keywords

t-cell prolymphocytic
8
prolymphocytic leukemia
8
peripheral edema
8
peripheral blood
8
t-cell
4
leukemia cerebriform
4
cerebriform variant
4
variant t-cell
4
leukemia t-pll
4
t-pll rare
4

Similar Publications

Proteasome Inhibitors Induce Apoptosis in Ex Vivo Cells of T-Cell Prolymphocytic Leukemia.

Int J Mol Sci

December 2024

Hematology Section, Department of Medicine, Hematology and Clinical Immunology Branch, University of Padova, 35122 Padova, Italy.

Finding an effective treatment for T-PLL patients remains a significant challenge. Alemtuzumab, currently the gold standard, is insufficient in managing the aggressiveness of the disease in the long term. Consequently, numerous efforts are underway to address this unmet clinical need.

View Article and Find Full Text PDF

Identification of t(X;1)(q28;q21) generating a novel GATAD2B::MTCP1 gene fusion in CMML and its persistence during progression to AML.

Hematology

December 2025

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Soochow University, Suzhou, People's Republic of China.

Objective: Hematological malignancies often involve chromosomal translocations and fusion genes that drive disease progression. While is well-known in T-cell prolymphocytic leukemia (T-PLL), its role in myeloid neoplasms is less understood. This report presents the first identification of the t(X;1)(q28;q21) translocation leading to the fusion in acute myeloid leukemia (AML) transformed from chronic myelomonocytic leukemia (CMML).

View Article and Find Full Text PDF

T-cell prolymphocytic leukemia (T-PLL) is a rare and highly aggressive mature T-cell neoplasm. Although the response rate to alemtuzumab, an anti-CD52 antibody, is high, it is difficult to cure the disease with this agent alone. Therefore, hematopoietic stem cell transplantation is recommended for eligible patients.

View Article and Find Full Text PDF

Antileukaemic rescue by dose-dense donor-lymphocyte infusions in T-PLL after allogeneic stem cell transplantation - a case report.

Ann Hematol

November 2024

Dept. Internal Medicine C, Haematology, Oncology, Stem Cell Transplantation, University Hospital Greifswald, Palliative Care. Ferdinand Sauerbruch Street, 17475, Greifswald, Germany.

T-Cell Prolymphocytic Leukaemia (T-PLL) is an aggressive disease with a poor prognosis and only curable by allogeneic stem cell transplantation. We describe the case of a male suffering from T-PLL. Therapy was alemtuzumab followed by an allograft from an unrelated donor.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!